These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16838599)

  • 1. [Uneven sex distribution in the cardiovascular trials--an exaggerated problem].
    Melander H; Rastad JA
    Lakartidningen; 2006 Jun 8-13; 103(23):1856-9. PubMed ID: 16838599
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventing vascular events due to elevated blood pressure.
    Yusuf S
    Circulation; 2006 May; 113(18):2166-8. PubMed ID: 16684871
    [No Abstract]   [Full Text] [Related]  

  • 3. [Post-infarction arterial hypertension: more benefits or more risks of the antihypertensive treatment?].
    Avanzini F; Alli C
    G Ital Cardiol; 1997 Sep; 27(9):936-44. PubMed ID: 9378201
    [No Abstract]   [Full Text] [Related]  

  • 4. [Antihypertensive therapy: campaign of the giants].
    Füessl HS
    MMW Fortschr Med; 2005 Dec; 147(51-52):28. PubMed ID: 16402700
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treating essential hypertension. Are beta blockers still first choice?].
    Rahn KH
    MMW Fortschr Med; 2007 May; 149(18):43-5. PubMed ID: 17672414
    [No Abstract]   [Full Text] [Related]  

  • 7. Letter by barrios et Al regarding article, "heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial".
    Barrios V; Escobar C; Echarri R
    Circulation; 2009 Aug; 120(5):e31; author reply e32. PubMed ID: 19652116
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study.
    Fossum E; Gleim GW; Kjeldsen SE; Kizer JR; Julius S; Devereux RB; Brady WE; Hille DA; Lyle PA; Dahlöf B
    J Intern Med; 2007 Oct; 262(4):439-48. PubMed ID: 17875180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
    Bangalore S; Messerli FH; Franklin SS; Mancia G; Champion A; Pepine CJ
    Eur Heart J; 2009 Jun; 30(11):1395-401. PubMed ID: 19351690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter by Ben-Dov and Bursztyn regarding article, "Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial".
    Ben-Dov IZ; Bursztyn M
    Circulation; 2007 Jan; 115(2):e18; author reply e19. PubMed ID: 17228008
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy.
    Khakoo AY; Yeh ET
    Nat Clin Pract Oncol; 2008 Nov; 5(11):655-67. PubMed ID: 18797437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiology 2008].
    Hoppe UC; Erdmann E
    Dtsch Med Wochenschr; 2008 Jun; 133(25-26):1341-3. PubMed ID: 18553258
    [No Abstract]   [Full Text] [Related]  

  • 14. The difficult task of finding the best antihypertensive agent: comment on "antihypertensive treatment and development of heart failure in hypertension".
    Frankenstein L
    Arch Intern Med; 2011 Mar; 171(5):394-5. PubMed ID: 21059966
    [No Abstract]   [Full Text] [Related]  

  • 15. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis.
    Bangalore S; Wild D; Parkar S; Kukin M; Messerli FH
    J Am Coll Cardiol; 2008 Sep; 52(13):1062-72. PubMed ID: 18848139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A vascular protective concept in hypertension and heart failure.
    Bühler FR; Ball SG; Baumgartner HR; Ertem G; Ferrannini E; Goldstein S; Karpov YA; Kiowski W; Widmann T; Zanchetti A
    J Cardiovasc Pharmacol; 1994; 24 Suppl 3():S1-4. PubMed ID: 7700058
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardioprotection with beta-blockers: myths, facts and Pascal's wager.
    Messerli FH; Bangalore S; Yao SS; Steinberg JS
    J Intern Med; 2009 Sep; 266(3):232-41. PubMed ID: 19702791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
    Coleman JJ; Kendall MJ
    J Clin Pharm Ther; 2006 Aug; 31(4):299-307. PubMed ID: 16882098
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of the Canadian Hypertension Education Programme in its first decade.
    McAlister FA; Feldman RD; Wyard K; Brant R; Campbell NR;
    Eur Heart J; 2009 Jun; 30(12):1434-9. PubMed ID: 19454575
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.